Six‐year experience with treatment of early donor‐specific anti‐HLA antibodies in pediatric lung transplantation using a human immunoglobulin‐based protocol

Authors:

Abstract
Objectives: Experience with the treatment of early donor‐specific anti‐HLA antibodies (eDSA) after lung transplantation in children is very limited. At our institution, we have treated patients with eDSA since 2013 with successive infusions of intravenous human immunoglobulins (IVIG), combined in some cases with a single dose of Rituximab and plasmapheresis (therapeutic plasma exchange [tPE]) or immunoabsorption. The aim of this study was to present the 6‐year results of IVIG‐based therapy in pediatric lung recipients.Methods: Records of pediatric (P = .65); freedom (%) from chronic lung allograft rejection (CLAD) was 89 vs 78 (P = .82); and from infection 47 vs 31 (P = .15), in IVIG vs control patients, respectively.Conclusions: After lung transplantation, an IVIG‐based treatment for eDSA yielded high eDSA clearance. IVIG and control patients showed similar CLAD‐free and graft survival.

This publication has 32 references indexed in Scilit: